• Investing
  • Stock
Round Table Thoughts
  • Economy
  • Editor’s Pick
Home Stock Ozempic Set the Stage, But Could Novo’s Newest Drug Be the Real Moneymaker?
Stock

Ozempic Set the Stage, But Could Novo’s Newest Drug Be the Real Moneymaker?

by March 8, 2024
by March 8, 2024 0 comment
Share
0
FacebookTwitterPinterestWhatsapp

If you ran a StockCharts scan for Runaway Gaps (Runaway Gap Ups) on Thursday, you would have come across only 12 stocks. Among them, the most recognizable name was Novo Nordisk A S (NVO), the Danish pharma company best known as the developer of the popular diabetes II drug, Ozempic.

Having already gained 26% since January, NVO jumped over 9% after reporting successful early trial results for its new weight loss drug, amycretin. Trial participants who took the drug achieved an average weight loss reduction of 13.1% over a 12-week period.

Wall Street sentiment is betting on the possibility that this new drug will be just as big as, if not bigger than, Ozempic, and some investors want to get in early. It’s easy to see why by simply looking at a weekly chart plotted over five years, covering the time when Ozempic became mainstreamed not only as a diabetes drug, but as a weight loss drug.

CHART 1: WEEKLY CHART OF NOVO. Notice the significant strength and momentum of the uptrend over a five-year period. The demand for weight loss is virtually “inelastic” these days.

Looking at the 50-, 100-, and 200-week Simple Moving Averages, not only are have they been fanning-out in full sail since Ozempic ads have began penetrating the mainstream consciousness, but NVO appears to be stretching the MAs to breaking point (if you can imagine such a thing), defying gravity with only the slightest indication (yet) of a potential pullback.

The daily picture gives us a clearer picture, not only of the strength of NOV’s performance, but of potential entry points should you want to go long.

CHART 2. DAILY CHART OF NVO. Not only does this look like a microcosm of the longer-term weekly chart, it also illustrates a similar trend relative to the broader market, its sector, and industry.

Runaway gaps, characterized as strong bullish continuation patterns, are located in the middle of a trend. But trends can only be confirmed looking backwards; we’re not there yet. So, are we looking at an exhaustion gap instead, one on the verge of a pullback?

Note the divergence between NOV’s price surge and the Money Flow Index (MFI) reading. As a volume-weighted RSI of sorts and an indicator to gauge momentum and anticipate possible reversals, the divergence we’re seeing hints at a potential dip in NVO’s share price.

Despite this, note NVO’s strong outperformance relative to the S&P 500 (+17%), its own sector via SPDR Health Care Select Sector Fund XLV (+20%), and the Dow Jones U.S. Pharmaceuticals Index or $DJUSPR (+23%).

The 50-day SMA and the Kumo segment of an Ichimoku Cloud has been plotted to show a potential landing point if a pullback were to occur. And if NVO were to pull back now, drawing a Fibonacci retracement from the October 2023 low would give us a 50% level right at $112.50, so we’re looking at the range, mostly covered within the “cloud.”

The Bottom Line

But here’s where you really have to think for yourself. Ozempic fever drove NVO’s seven-year uptrend, and arguably, it isn’t over yet. The most recent surge is driven by sentiment and speculation surrounding that amycretin will bolster and continue NVO’s winning streak. The $112 to $118 range may be a reasonable “technical” entry point, but with a PEG (Price to Earnings to Growth) ratio of 4.87, it’s far from being undervalued.

How to Run a StockCharts Scan

Finding the right stocks and exchange-traded funds (ETFs) to trade can be tricky. But with a little work, you can create a strategy that identifies a few promising prospects.

Fortunately, it isn’t too hard to learn how. Just stick to these steps:

Select (or create) a few different scan criteriaBe sure to run these scans regularlyAnalyze the stocks (or ETFs)  that your scan has identifiedDetermine your overall trading setup (including your entry and exit criteria)

The StockCharts Scan Engine is useful for narrowing down stocks and ETFs that match certain requirements. It comes with a bunch of ready-made scans that are a good starting point. As you get the hang of these scans, you can adjust them or create new ones that align with your trading goals.

For example, this article was prompted by a Runaway Gap Ups scan. As you can imagine, there are plenty more scans you can run. Try out the StockCharts Sample Scan Library (Charts & Tools > Sample Scan Library)

You Might Also Like
  • New Industry Group Golden Cross Indexes and Silver Cross Indexes
  • AI Boom Meets Tariff Doom: How to Time Semiconductor Stocks
  • SCTR Report: Unlocking TSLA’s Potential—What Every Investor Needs to Know Now
  • Sector Rotation Update: Value Stocks and Bonds Lead the Way!
Share
0
FacebookTwitterPinterestWhatsapp

previous post
Top 10 Actionable Charts to Watch 2024
next post
Clear Split in NY FANG+ Universe Offers Pair Trading Universe

You may also like

Equity and Inflation Outlook — Watch These Videos!

November 21, 2023

Identifying GREAT Trades and Looking Ahead to 2025 Using RRG...

December 13, 2024

The Mighty Have Fallen! TSLA and NVDA On The Rocks

March 15, 2024

Dow Theory Bull Confirmed! What Happens Next?

July 16, 2024

Buy the Dips!

July 8, 2023

Bitcoin Blasts ABOVE 70K!

May 21, 2024

Nasdaq 100 (QQQ), Communication Services (XLC) and Transports (IYT) New...

October 13, 2023

Growth Stocks Seen THRIVING in Anticipation of NVDA Earnings

August 23, 2023

Master The Most Underutilized Options Income Strategy: Cash-Secured Puts

May 15, 2024

Top 10 Charts to Watch for February 2025

February 7, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • The Unpredictable Stock Market: How to Make Sense of It

      May 8, 2025
    • AMD CEO calls China a ‘large opportunity’ and warns against strict U.S. chip controls

      May 7, 2025
    • NBA star Russell Westbrook launches AI-enabled funeral planning startup

      May 7, 2025
    • Use This Multi-Timeframe MACD Signal for Precision Trades

      May 7, 2025
    • Judge allows lawsuit over Burger King’s Whopper ads to move forward

      May 7, 2025

    Popular Posts

    • 1

      Trump-era China sanctions ended by Biden may be...

      June 27, 2024 2,630 views
    • 2

      Walz’s honeymoon with China gets fresh scrutiny as...

      August 9, 2024 2,339 views
    • 3

      Biden appointee played key role in recruiting Chinese...

      June 25, 2024 2,320 views
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful...

      July 10, 2024 2,302 views
    • 5

      Harris VP pick spent years promoting research facility...

      August 29, 2024 2,185 views

    Categories

    • Economy (7,009)
    • Editor's Pick (2,064)
    • Investing (538)
    • Stock (2,529)

    Popular Posts

    • 1

      Trump-era China sanctions ended by Biden may be revived under new House GOP bill

      June 27, 2024
    • 2

      Walz’s honeymoon with China gets fresh scrutiny as Harris camp blasts ‘lying’ critics

      August 9, 2024
    • 3

      Biden appointee played key role in recruiting Chinese businesses to Delaware: ‘Longtime friends’

      June 25, 2024
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful of Chinese spy threats

      July 10, 2024
    • 5

      Harris VP pick spent years promoting research facility that collaborated with ‘Chinese military company’

      August 29, 2024

    Latest News

    • The Unpredictable Stock Market: How to Make Sense of It

      May 8, 2025
    • AMD CEO calls China a ‘large opportunity’ and warns against...

      May 7, 2025
    • NBA star Russell Westbrook launches AI-enabled funeral planning startup

      May 7, 2025

    Categories

    • Economy (7,009)
    • Editor's Pick (2,064)
    • Investing (538)
    • Stock (2,529)

    Disclaimer: RoundTableThoughts.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 RoundTableThoughts.com. All Rights Reserved.

    Round Table Thoughts
    • Investing
    • Stock
    Round Table Thoughts
    • Economy
    • Editor’s Pick

    Read alsox

    Finance, Family, Society: Finding a Good...

    March 8, 2023

    Further Inversion of Yield Curve Pushes...

    July 26, 2023

    Economic Modern Family: More to Prove...

    February 13, 2023
    Sign In

    Keep me signed in until I sign out

    Forgot your password?

    Password Recovery

    A new password will be emailed to you.

    Have received a new password? Login here